Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$38.81 - $72.83
Previous CloseN/A
Volume846.89K
Average Volume (3M)3.80M
Market Cap
$10.60B
Enterprise Value$11.72B
Total Cash (Recent Filing)$858.43M
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Oct 29, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding189,319,100
10 Day Avg. Volume3,276,429
30 Day Avg. Volume3,799,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit5.84
Enterprise Value/Ebitda-14.31
Forecast
1Y Price Target
$64.44Price Target Upside15.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Product DevelopmentThe core Cologuard brand has a strong foundation, and the introduction of Cologuard Plus is gaining momentum, potentially leading to significant revenue growth.
Revenue GrowthThe company generated total revenue of $811.1 million, with Screening revenue increasing 18% and Precision Oncology revenue up 9%, showcasing strong financial performance.
Strategic PartnershipsExact Sciences' acquisition of exclusive rights to Freenome's blood-based colorectal cancer screening tests should mitigate competition risk and strengthen its position in the market.
Bears Say
Market PositionCRC blood is viewed as a second-line option compared to Cologuard Plus, indicating a potential limitation in its primary market positioning.
Regulatory DelaysEXAS is unlikely to launch Freenome's assay until it receives FDA approval, placing it at least 2 years behind competitor GH Shield.
Trial ResultsThe disappointing BLUE-C LBx results landed below the NCD requirement of 74% sensitivity, yielding a test that is very unlikely to have commercial potential.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $38.81 and its highest was $72.83 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $10.60B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Oct 29, 2025 which is in 47 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Aug 06, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.126 by $0.116.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is >-0.01.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 189,319,100 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.126. Following the earnings report the stock price went down -7.994%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.44 (15.07% Upside)
$64.44 (15.07% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 958.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.66%
12-Months-Change
Fundamentals
Return on Equity
-35.51%
Trailing 12-Months
Asset Growth
-13.13%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Company Deck
EXAS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong operational and financial performance with record-breaking results and increased guidance. However, the disappointment from the blood-based test results and reliance on external technology for CRC blood screening pose challenges. Nonetheless, the expansion of Cologuard Plus and new product launches demonstrate robust growth potential.View all EXAS earnings summariesEXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$64.44
▲(15.07% Upside)
Technical Analysis
Ownership Overview
1.05% Insiders
46.04% Mutual Funds
29.48% Other Institutional Investors
8.22% Public Companies and Individual Investors